202 related articles for article (PubMed ID: 12181637)
1. Is there anticipation in the age at onset of cancer in families with Li-Fraumeni syndrome?
Trkova M; Hladikova M; Kasal P; Goetz P; Sedlacek Z
J Hum Genet; 2002; 47(8):381-6. PubMed ID: 12181637
[TBL] [Abstract][Full Text] [Related]
2. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
3. [When is it useful to look for TP53 germline gene mutations in families of oncology patients?].
Trková M; Sedlácek Z
Cas Lek Cesk; 2003; 142(4):220-5. PubMed ID: 12841124
[TBL] [Abstract][Full Text] [Related]
4. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.
Gonzalez KD; Noltner KA; Buzin CH; Gu D; Wen-Fong CY; Nguyen VQ; Han JH; Lowstuter K; Longmate J; Sommer SS; Weitzel JN
J Clin Oncol; 2009 Mar; 27(8):1250-6. PubMed ID: 19204208
[TBL] [Abstract][Full Text] [Related]
5. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome.
Tabori U; Nanda S; Druker H; Lees J; Malkin D
Cancer Res; 2007 Feb; 67(4):1415-8. PubMed ID: 17308077
[TBL] [Abstract][Full Text] [Related]
6. Telomere length in peripheral blood cells of germline TP53 mutation carriers is shorter than that of normal individuals of corresponding age.
Trkova M; Prochazkova K; Krutilkova V; Sumerauer D; Sedlacek Z
Cancer; 2007 Aug; 110(3):694-702. PubMed ID: 17567834
[TBL] [Abstract][Full Text] [Related]
7. High frequency of de novo mutations in Li-Fraumeni syndrome.
Gonzalez KD; Buzin CH; Noltner KA; Gu D; Li W; Malkin D; Sommer SS
J Med Genet; 2009 Oct; 46(10):689-93. PubMed ID: 19556618
[TBL] [Abstract][Full Text] [Related]
8. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome.
Birch JM; Blair V; Kelsey AM; Evans DG; Harris M; Tricker KJ; Varley JM
Oncogene; 1998 Sep; 17(9):1061-8. PubMed ID: 9764816
[TBL] [Abstract][Full Text] [Related]
9. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
10. Joint effects of germ-line p53 mutation and sex on cancer risk in Li-Fraumeni syndrome.
Wu CC; Shete S; Amos CI; Strong LC
Cancer Res; 2006 Aug; 66(16):8287-92. PubMed ID: 16912210
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families.
Bougeard G; Sesboüé R; Baert-Desurmont S; Vasseur S; Martin C; Tinat J; Brugières L; Chompret A; de Paillerets BB; Stoppa-Lyonnet D; Bonaïti-Pellié C; Frébourg T;
J Med Genet; 2008 Aug; 45(8):535-8. PubMed ID: 18511570
[TBL] [Abstract][Full Text] [Related]
12. [Li-Fraumeni syndrome].
Frebourg T
Bull Cancer; 1997 Jul; 84(7):735-40. PubMed ID: 9339200
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel TP53 mutations in familial and sporadic cancer cases of German and Swiss origin.
Bendig I; Mohr N; Kramer F; Weber BH
Cancer Genet Cytogenet; 2004 Oct; 154(1):22-6. PubMed ID: 15381368
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.
Birch JM; Hartley AL; Tricker KJ; Prosser J; Condie A; Kelsey AM; Harris M; Jones PH; Binchy A; Crowther D
Cancer Res; 1994 Mar; 54(5):1298-304. PubMed ID: 8118819
[TBL] [Abstract][Full Text] [Related]
15. Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.
Varley JM; McGown G; Thorncroft M; Santibanez-Koref MF; Kelsey AM; Tricker KJ; Evans DG; Birch JM
Cancer Res; 1997 Aug; 57(15):3245-52. PubMed ID: 9242456
[TBL] [Abstract][Full Text] [Related]
16. Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li-Fraumeni cancer predisposition syndrome.
Ariffin H; Hainaut P; Puzio-Kuter A; Choong SS; Chan AS; Tolkunov D; Rajagopal G; Kang W; Lim LL; Krishnan S; Chen KS; Achatz MI; Karsa M; Shamsani J; Levine AJ; Chan CS
Proc Natl Acad Sci U S A; 2014 Oct; 111(43):15497-501. PubMed ID: 25313051
[TBL] [Abstract][Full Text] [Related]
17. [Germline mutations of the p53 gene].
Frebourg T
Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
[TBL] [Abstract][Full Text] [Related]
18. Relative frequency and morphology of cancers in carriers of germline TP53 mutations.
Birch JM; Alston RD; McNally RJ; Evans DG; Kelsey AM; Harris M; Eden OB; Varley JM
Oncogene; 2001 Aug; 20(34):4621-8. PubMed ID: 11498785
[TBL] [Abstract][Full Text] [Related]
19. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.
Palmero EI; Achatz MI; Ashton-Prolla P; Olivier M; Hainaut P
Curr Opin Oncol; 2010 Jan; 22(1):64-9. PubMed ID: 19952748
[TBL] [Abstract][Full Text] [Related]
20. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
